Literature DB >> 6627215

Primary gastric lymphoma. An analysis with emphasis on prognostic factors and radiation therapy.

D S Shimm, D E Dosoretz, T Anderson, R M Linggood, N L Harris, C C Wang.   

Abstract

Primary gastric lymphoma, lymphoma originating in the stomach, without involvement of peripheral or mediastinal lymph nodes, viscera, or the bloodstream, is sufficiently uncommon that the indications for radiation therapy, the dose of irradiation necessary for control of lymphoma, optimum field size, and patterns of failure have never been established. The authors identified 26 patients, and reviewed their charts and pathologic material. Their overall 5-year survival was 57%. Factors significantly influencing 5-year survival were serosal penetration (32% versus 91%), regional lymph node involvement (33% versus 81%), and location on the lesser curvature (20% versus 89%). Histologic characteristics, extent of surgery, and, provided the patient was irradiated, involvement of surgical margins did not influence survival. Overall, survival was not affected by irradiation, but in patients with poor prognostic factors there appeared to be a beneficial effect. Analysis of local control in this and other series suggests that patients should receive at least 40 Gy, and that whole abdominal irradiation is not necessary. The majority of failures were distant, indicating a need for effective systemic therapy.

Entities:  

Mesh:

Year:  1983        PMID: 6627215     DOI: 10.1002/1097-0142(19831201)52:11<2044::aid-cncr2820521113>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Primary non-Hodgkin's lymphoma of the stomach: three radical modalities of treatment in 75 patients.

Authors:  I B Shchepotin; S R Evans; M Shabahang; V Chorny; R R Buras; V Korobko; A Zadorozhny; R J Nauta
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

2.  The bcl-2 gene in primary B cell lymphoma of mucosa-associated lymphoid tissue (MALT).

Authors:  L Pan; T C Diss; D Cunningham; P G Isaacson
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

3.  Is an aggressive surgical approach to the patient with gastric lymphoma warranted?

Authors:  C B Rosen; J A van Heerden; J K Martin; L E Wold; D M Ilstrup
Journal:  Ann Surg       Date:  1987-06       Impact factor: 12.969

4.  Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.

Authors:  R Heinz; H Hanak; A Stacher
Journal:  Klin Wochenschr       Date:  1985-07-15

Review 5.  Primary gastric lymphoma.

Authors:  Ahmad M Al-Akwaa; Neelam Siddiqui; Ibrahim A Al-Mofleh
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 6.  Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma.

Authors:  Daniel Rolf; Gabriele Reinartz; Stephan Rehn; Christopher Kittel; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

7.  Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease.

Authors:  Fatih Selçukbiricik; Deniz Tural; Olgun Elicin; Selin Berk; Mustafa Ozgüroğlu; Nuran Bese; Burhan Ferhanoglu
Journal:  ISRN Oncol       Date:  2012-08-29

8.  Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas.

Authors:  G Bellesi; R Alterini; A Messori; A Bosi; F Bernardi; S di Lollo; P R Ferrini
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

9.  Primary gastric lymphoma--the experience of a general hospital.

Authors:  T Economopoulos; C Alexopoulos; N Stathakis; S Styloyannis; J Dervenoulas; S Tsousis; S Raptis
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

10.  Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment.

Authors:  Luis Miguel Juárez-Salcedo; Lubomir Sokol; Julio C Chavez; Samir Dalia
Journal:  Cancer Control       Date:  2018 Jan-Mar       Impact factor: 3.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.